Us regulators approved the use of radioactive compounds, developed by Eli Lilly, for detection of the Tau protein, increased level of which indicates the development of Alzheimer’s disease.
New contrast agents are pertusier F18 (flortaucipir F18) are administered to patients intravenously before performing positron emission tomography of the brain. Development Eli Lilly became the first drug on the market that can be used to identify clusters (tangles) of Tau-protein in the brain. Such neurofibrillary tangles are one of the signs of Alzheimer’s disease.
Safety and efficacy were evaluated in two clinical studies in which five doctors studied and interpreted the images obtained with the introduction of pertusier. Part of the results of interpretation were compared with the pathologist’s report. These studies confirmed that the use of the drug allows high accuracy to determine the presence of neurofibrillary tangles.